The FDA has granted orphan drug designation to inobrodib (CCS1477) as a treatment for patients with multiple myeloma, according to a press release from CellCentric. Developers designed the orally available, first-in-class inobrodib for use at home without any need for intensive monitoring. Inobrodib is currently under evaluation as part of a phase 1/2a trial among patients with multiple myeloma and other hematologic cancers. Source: CancerNetwork.com 29/6/2023